Mouse pharmacological models of cognitive disruption relevant to schizophrenia
Schizophrenia is a debilitating cognitive disorder. The link between cognitive debilitation and functional outcome in patients with schizophrenia has prompted research to develop procognitive therapies. It is hoped that by improving cognition in these patients, their functional outcome will also imp...
Na minha lista:
Main Authors: | , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2011
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3217063/ https://ncbi.nlm.nih.gov/pubmed/21726569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2011.06.013 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
id |
pubmed-3217063 |
---|---|
record_format |
dspace |
spelling |
pubmed-32170632013-03-01 Mouse pharmacological models of cognitive disruption relevant to schizophrenia YOUNG, Jared W POWELL, Susan B GEYER, Mark A Neuropharmacology Article Schizophrenia is a debilitating cognitive disorder. The link between cognitive debilitation and functional outcome in patients with schizophrenia has prompted research to develop procognitive therapies. It is hoped that by improving cognition in these patients, their functional outcome will also improve. Although no established treatments exist as yet, progress has been made toward understanding how to evaluate putative compounds in the clinic. Genetic mouse models and pharmacological rat models of cognitive disruption are being developed that may help to evaluate these putative compounds preclinically. Considering the increased number of genetic mouse models relevant to schizophrenia, there is a need to evaluate pharmacological manipulations on cognition in mice. Here we review the current literature on mouse pharmacological models relevant to schizophrenia. In this review, we discuss where different pharmacological effects between rats and mice on cognitive tasks are observed and assess the validity offered by these models. We conclude that the predictive validity of these models is currently difficult to assess and that much more needs to be done to develop useful mouse pharmacological models of cognitive disruption in schizophrenia. 2011-06-29 2012-03 /pmc/articles/PMC3217063/ /pubmed/21726569 http://dx.doi.org/10.1016/j.neuropharm.2011.06.013 Text en © 2011 Elsevier Ltd. All rights reserved. |
institution |
US NLM |
collection |
PubMed Central |
language |
Inglês |
format |
Artigo |
topic |
Article |
spellingShingle |
Article YOUNG, Jared W POWELL, Susan B GEYER, Mark A Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
description |
Schizophrenia is a debilitating cognitive disorder. The link between cognitive debilitation and functional outcome in patients with schizophrenia has prompted research to develop procognitive therapies. It is hoped that by improving cognition in these patients, their functional outcome will also improve. Although no established treatments exist as yet, progress has been made toward understanding how to evaluate putative compounds in the clinic. Genetic mouse models and pharmacological rat models of cognitive disruption are being developed that may help to evaluate these putative compounds preclinically. Considering the increased number of genetic mouse models relevant to schizophrenia, there is a need to evaluate pharmacological manipulations on cognition in mice. Here we review the current literature on mouse pharmacological models relevant to schizophrenia. In this review, we discuss where different pharmacological effects between rats and mice on cognitive tasks are observed and assess the validity offered by these models. We conclude that the predictive validity of these models is currently difficult to assess and that much more needs to be done to develop useful mouse pharmacological models of cognitive disruption in schizophrenia. |
author |
YOUNG, Jared W POWELL, Susan B GEYER, Mark A |
author_facet |
YOUNG, Jared W POWELL, Susan B GEYER, Mark A |
author_sort |
YOUNG, Jared W |
title |
Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
title_short |
Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
title_full |
Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
title_fullStr |
Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
title_full_unstemmed |
Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
title_sort |
mouse pharmacological models of cognitive disruption relevant to schizophrenia |
publishDate |
2011 |
url |
https://ncbi.nlm.nih.gov/pmc/articles/PMC3217063/ https://ncbi.nlm.nih.gov/pubmed/21726569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2011.06.013 |
_version_ |
1756111051837931520 |